Short Interest Update on Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (EW) : The short interest in Edwards Lifesciences Corporation (EW) has increased from 3,695,611 to 3,731,543 from Jul 29, 2016, to August 15, 2016, indicating that the traders are bearish on the stock. On an average, 890,686 shares are traded daily in the stock and only 4 days are left for the shorts to cover. The short open interest is 1.8% of the total shares in the hands of the public. The shorts in the stock have gone up by 35,932 shares, which is an increase of 1% over the previous reading. The short interest information was released on Wednesday Aug 24th after the market close.

Edwards Lifesciences Corporation (NYSE:EW): The stock opened at $117.21 on Wednesday but the bulls could not build on the opening and the stock topped out at $117.58 for the day. The stock traded down to $114.17 during the day, due to lack of any buying support eventually closed down at $114.30 with a loss of -2.44% for the day. The stock had closed at $117.16 on the previous day. The total traded volume was 1,487,793 shares.


In a related news, The Securities and Exchange Commission has divulged that Mussallem Michael A, director officer (Chairman & CEO) of Edwards Lifesciences Corp, had unloaded 49,100 shares at an average price of $114.37 in a transaction dated on August 11, 2016. The total value of the transaction was worth $5,615,567.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.